VNDA Key Statistics, Chart & Performance
The current stock price of VNDA is 4.8 USD. In the past month the price decreased by -12.73%. In the past year, price decreased by -5.7%.
VNDA Latest News, Press Relases and Analysis
VNDA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About VNDA
Company Profile
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 368 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Company Info
VANDA PHARMACEUTICALS INC
Suite 300E, 2200 Pennsylvania Ave Nw
WASHINGTON WASHINGTON DC 20037 US
CEO: Mihael H. Polymeropoulos
Employees: 368
Phone: 12027343400
VANDA PHARMACEUTICALS INC / VNDA FAQ
What does VANDA PHARMACEUTICALS INC do?
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 368 full-time employees. The company went IPO on 2006-04-12. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
Can you provide the latest stock price for VANDA PHARMACEUTICALS INC?
The current stock price of VNDA is 4.8 USD. The price decreased by -0.83% in the last trading session.
Does VNDA stock pay dividends?
VNDA does not pay a dividend.
What is the ChartMill technical and fundamental rating of VNDA stock?
VNDA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of VANDA PHARMACEUTICALS INC (VNDA) based on its PE ratio?
VANDA PHARMACEUTICALS INC (VNDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
Should I buy VNDA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VNDA.
What is the market capitalization of VNDA stock?
VANDA PHARMACEUTICALS INC (VNDA) has a market capitalization of 283.63M USD. This makes VNDA a Micro Cap stock.
VNDA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to VNDA. When comparing the yearly performance of all stocks, VNDA turns out to be only a medium performer in the overall market: it outperformed 42.11% of all stocks.
VNDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VNDA. VNDA has a medium profitability rating, but doesn't score so well on its financial health evaluation.
VNDA Financial Highlights
Over the last trailing twelve months VNDA reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS decreased by -407.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| Debt/Equity | 0.01 |
VNDA Forecast & Estimates
9 analysts have analysed VNDA and the average price target is 11.99 USD. This implies a price increase of 149.69% is expected in the next year compared to the current price of 4.8.
For the next year, analysts expect an EPS growth of -471.62% and a revenue growth 11.7% for VNDA